RxDoctor Payments DataLook up a doctor →

Jie He, MD

Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1124259353

Payments from drug & device makers

$26,067in general payments, 2019–2025

Across 896 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Lilly USA, LLC$4K
  • Sanofi-aventis U.S. LLC$2K
  • AstraZeneca$2K
  • Amneal Pharmaceuticals LLC$2K
  • Corcept Therapeutics$1K
  • plus $11K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk112$4,064
Lilly USA, LLC163$3,872
Sanofi-aventis U.S. LLC68$2,448
AstraZeneca35$1,648
Amneal Pharmaceuticals LLC87$1,634
Corcept Therapeutics41$1,396
AbbVie52$920
Gilead8$887
Bayer40$871
Amgen(2 entities)30$737
Dexcom, Inc.14$730
Abbott22$512
Boehringer Ingelheim15$508
Vivus LLC21$412
Insulet Corporation12$385
Xeris Pharmaceuticals, Inc.22$381
Madrigal Pharmaceuticals4$304
Medtronic(3 entities)9$294
Amarin Pharma, Inc.16$257
Zealand Pharma US, Inc.7$247
Antares Pharma, Inc.9$238
Cequr Corporation3$224
Pfizer10$208
Radius Health, Inc.11$207
IBSA Pharma Inc.11$196
Shire North American Group Inc6$181
GSK3$169
Mannkind Corporation8$167
Genentech USA, Inc.2$165
Astellas Pharma US Inc2$143
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$131
Phathom Pharmaceuticals, Inc.1$125
Sunovion Pharmaceuticals Inc.1$125
Noven Pharmaceuticals, Inc.1$125
Eisai Inc.1$125
BETA Bionics, Inc.1$102
ARS Pharmaceuticals Operations, Inc.1$100
Merck6$96
Tandem Diabetes Care, Inc.2$96
Vertos Medical, Inc.1$78
Ascendis Pharma Endocrinology Inc3$65
Takeda Pharmaceuticals U.S.A., Inc.3$65
Lifescan, Inc.4$58
Sequel Med Tech, LLC2$54
Recordati_rare_diseases_inc.3$42
Alvogen Inc2$41
Currax Pharmaceuticals LLC2$32
Novartis1$22
Almatica Pharma LLC1$22
Halozyme Inc1$20
Johnson & Johnson1$20
Ultragenyx Pharmaceutical Inc.1$20
RGH Enterprises LLC1$19
Acerus Pharmaceuticals Corporation1$16
Verity Pharmaceuticals Inc.1$16
EUSA Pharma (US) LLC1$15
Ascensia Diabetes Care US Inc.1$15
Amphastar Pharmaceuticals, Inc.1$15

How this compares

$26,067 in reported general payments places this provider in the 85th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Medicare billing

Part B allowed, 2024
$240,662
Medicare patients
521
Services billed
2,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Rockville

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →